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Background
BAY 63–2521 is an oral soluble guanylate cyclase (sGC)
stimulator that acts independently of nitric oxide (NO). It
targets the reduced form of sGC, and enhances the sensi-
tivity of the enzyme to low levels of bioavailable NO.
Phase I clinical trial results suggest that BAY 63–2521 has
a favourable safety profile in healthy volunteers. This
proof-of-concept study evaluated BAY 63–2521 in
patients with moderate-to-severe pulmonary hyperten-
sion (pulmonary vascular resistance [PVR] > 300
dyn·s·cm-5).
Materials and methods
This two-part non-randomized, non-blinded, single-site
study assessed safety, tolerability, cardiopulmonary
haemodynamics, gas exchange and ventilation-perfusion
mismatch (VQM). Tolerability of 2.5 mg and 5 mg total
doses of BAY 63–2521 was evaluated in 2 × 2 patients
given hourly incremental doses (0.5 + 1 + 1 mg = 2.5 mg;
1 + 2 + 2 mg = 5 mg). Further evaluation of 1 mg and 2.5
mg doses was performed in 15 patients and included
Swan-Ganz haemodynamics, multiple inert gas elimina-
tion technique (MIGET) and blood gas analysis. Results
were compared with peak intervention values for inhaled
NO (iNO) (8–20 ppm) and one-time post-NO-interven-
tion baseline values. Adverse events (AEs), vital signs,
electrocardiograms (ECGs) and laboratory values were
monitored.
Results
Baseline measurements in the 2.5 mg group were 42.1 ±
11.3 mmHg mean pulmonary arterial pressure (mPAP),
566 ± 209 dyn·s·cm-5 PVR, 133 ± 20 mmHg systolic
blood pressure (SBP), and 2.74 ± 0.82 L/min/m2 cardiac
index. BAY 63–2521 was well tolerated up to 2.5 mg,
while 5.0 mg caused asymptomatic hypotension in one
patient. Six mild AEs (three of which were attributed to
BAY 63–2521) occurred in 4 of 19 patients, all resolving
by study completion. No serious AEs occurred. BAY 63–
2521 had no clinically relevant effects on vital signs, ECGs
or laboratory values. No major changes were noted in
blood gases or VQM. BAY 63–2521 dose-dependently (1
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mg and 2.5 mg, P < 0.0001 each) reduced mPAP, PVR,
SBP, systemic vascular resistance (SVR), and increased the
cardiac index (Table 1), while maintaining mean SBP
above 110 mmHg. These effects were significantly greater
than those of iNO for SBP, SVR, PVR and cardiac index,
and approached significance for mPAP. Effects correlated
closely with plasma concentrations.
Conclusion
BAY 63–2521 has a favourable safety profile and does not
alter gas exchange or VQM at single doses up to 2.5 mg in
patients with moderate-to-severe pulmonary hyperten-
sion. This agent improved all main haemodynamic
parameters in a dose-dependent manner and to a greater
extent than iNO. BAY 63–2521 has therapeutic potential
and further studies are warranted.
Table 1: Haemodynamic effects of BAY 63–2521, 2.5 mg
SBP (mmHg) SVR (dyn·s·cm-5) mPAP (mmHg) PVR (dyn·s·cm-5) Cardiac index (L/min/m2)
vs baseline -28.6*** -545.9*** -5.1** -168.1* 0.95***
Vs iNO -25.7*** -541.5*** -3.1 -132.9* 0.89***
*P < 0.05; **P < 0.005; ***P < 0.0001Page 2 of 2
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